[Research advances in HIV pre-exposure prophylaxis drug].
Zhonghua Liu Xing Bing Xue Za Zhi
; 43(12): 2036-2040, 2022 Dec 10.
Article
em Zh
| MEDLINE
| ID: mdl-36572482
ABSTRACT
In 2012, the World Health Organization (WHO) released tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis drug to help people at risk of HIV infection in specific populations, and various clinical trials and real-world data have confirmed the effectiveness of TDF/FTC in preventing HIV infection. In 2019, propofol tenofovir combined with emtricitabine (TAF/FTC) was approved in the United States as the second oral drug for pre-exposure prophylaxis(PrEP). However, for people who cannot take the drug or have poor adherence to the drug, second-generation PrEP, or long-acting antiretrovirals, provide more options. This artical reviewed the research progress of the first generation of oral PrEP and the new PrEP developed in recent years to provide reference for the promotion of HIV PrEP in China.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
/
Profilaxia Pré-Exposição
Idioma:
Zh
Ano de publicação:
2022
Tipo de documento:
Article